Literature DB >> 2106767

Outcome assessment in cardiovascular cost-benefit studies.

B O'Brien1, J Rushby.   

Abstract

The scarcity of health resources and development of new treatments have introduced a need to assess health care interventions in the areas of both costs and benefits. Information on costs and benefits of one treatment program relative to another can assist decisions about resource allocation by indicating which interventions offer the greatest benefit at the least cost. Economic evaluation is dependent on accurate definition and appropriate measurement of outcome or benefit. This article reviews a number of evaluation techniques and cost-benefit studies associated with cardiovascular medicine. The focus is on health-related quality of life, the methodology, and the problems encountered therein. Methods for combining quantity and quality of life are discussed with reference to a composite measure of health outcome, quality-adjusted life years.

Mesh:

Year:  1990        PMID: 2106767     DOI: 10.1016/s0002-8703(05)80055-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  DRG-based cost minimization models: applications in a hospital environment.

Authors:  Sakesun Suthummanon; Vincent K Omachonu
Journal:  Health Care Manag Sci       Date:  2004-08

Review 2.  The economics and cost-effectiveness of critical care medicine.

Authors:  D B Chalfin; I L Cohen; J Lambrinos
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

Review 3.  Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.

Authors:  T van der Weijden; J A Knottnerus; A J Ament; H E Stoffers; R P Grol
Journal:  J Epidemiol Community Health       Date:  1998-09       Impact factor: 3.710

Review 4.  Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.

Authors:  K S Woo; H D White
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 5.  Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.

Authors:  J W Hay; W M Yu; T Ashraf
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.